Alector discontinues Phase 2 trial of nivisnebart for early Alzheimer's disease

9 articles · Updated · MarketWatch · Apr 29

The Phase 2 PROGRESS-AD trial, co-developed with GSK, is being halted as it is unlikely to achieve its primary endpoint of slowing disease progression.
Alector's decision reflects challenges in developing effective treatments for Alzheimer's, disappointing patients and families affected by the disease.
Despite this setback, Alector states it remains committed to advancing other neurodegenerative disease programs.

How will this latest failure affect Alector’s crucial partnership with pharma giant GSK?

Alector's drug targeted a high-risk gene. Was this a bold scientific failure or a reckless business gamble?

With another Alzheimer's drug failing, is the entire research strategy for the disease fundamentally flawed?

Alector's stock is high despite huge losses. Is this a bubble or faith in its next big drug?

After so many high-profile setbacks, will investment in Alzheimer's research begin to dry up?

Could AI and gene editing succeed where traditional Alzheimer's drug trials have repeatedly failed?